Immunological markers that predict radiation toxicity

Cancer Letters

Volumn 368, Issue 2, 2015, Pages 191-197

  Sprung, Carl N ^a,b   Forrester, Helen B ^a,b   Siva, Shankar ^c,d   Martin, Olga A ^c,d  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Biomarker; Immunology; Inflammation; Radiation sensitivity; Radiotherapy

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

CANCER PATIENT; CANCER RADIOTHERAPY; DISEASE ASSOCIATION; DISEASE MARKER; FIBROSIS; HUMAN; IMMUNE RESPONSE; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RADIATION INJURY; SHORT SURVEY; TREATMENT RESPONSE; ANIMAL; GENETICS; IMMUNOLOGY; INFLAMMATION; NEOPLASMS; PREDICTIVE VALUE; PROCEDURES;

ANIMALS; BIOMARKERS, TUMOR; HUMANS; INFLAMMATION; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RADIATION INJURIES; RADIOTHERAPY;

EID: 84941875313     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.045     Document Type: Review

References (93)

1. Baskar R., Lee K.A., Yeo R., Yeoh K.W. Cancer and radiation therapy: current advances and future directions. Int. J. Med. Sci 2012, 9:193-199.
2. Belot J. Radiotherapy in Skin Disease 1905, Rebman, London, United Kingdom.
3. Delaney G., Jacob S., Featherstone C., Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005, 104:1129-1137.
4. Haikerwal S.J., Hagekyriakou J., MacManus M., Martin O.A., Haynes N.M. Building immunity to cancer with radiation therapy. Cancer Lett 2015.
5. Andreassen C.N., Alsner J., Overgaard J. Does variability in normal tissue reactions after radiotherapy have a genetic basis - where and how to look for it?. Radiother. Oncol 2002, 64:131-140.
6. Barnett G.C., West C.M., Dunning A.M., Elliott R.M., Coles C.E., Pharoah P.D., et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat. Rev. Cancer 2009, 9:134-142.
7. Forrester H.B., Li J., Leong T., McKay M.J., Sprung C.N. Identification of a radiation sensitivity gene expression profile in primary fibroblasts derived from patients who developed radiotherapy-induced fibrosis. Radiother. Oncol 2014, 111:186-193.
8. Gatti R.A. The inherited basis of human radiosensitivity. Acta Oncol 2001, 40:702-711.
9. Ho A.Y., Atencio D.P., Peters S., Stock R.G., Formenti S.C., Cesaretti J.A., et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int. J. Radiat. Oncol. Biol. Phys 2006, 65:646-655.
10. Barnett G.C., Thompson D., Fachal L., Kerns S., Talbot C., Elliott R.M., et al. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother. Oncol 2014, 111:178-185.
11. Fachal L., Gomez-Caamano A., Barnett G.C., Peleteiro P., Carballo A.M., Calvo-Crespo P., et al. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat. Genet 2014.
12. Henriquez Hernandez L.A., Lara P.C., Pinar B., Bordon E., Rodriguez Gallego C., Bilbao C., et al. Constitutive gene expression profile segregates toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat. Oncol 2009, 4:17.
13. Quarmby S., West C., Magee B., Stewart A., Hunter R., Kumar S. Differential expression of cytokine genes in fibroblasts derived from skin biopsies of patients who developed minimal or severe normal tissue damage after radiotherapy. Radiat. Res 2002, 157:243-248.
14. Rieger K.E., Hong W.J., Tusher V.G., Tang J., Tibshirani R., Chu G. Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:6635-6640.
15. Rodningen O.K., Borresen-Dale A.L., Alsner J., Hastie T., Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother. Oncol 2008, 86:314-320.
16. Svensson J.P., Stalpers L.J., Esveldt-van Lange R.E., Franken N.A., Haveman J., Klein B., et al. Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med 2006, 3:e422.
17. Quarmby S., Fakhoury H., Levine E., Barber J., Wylie J., Hajeer A.H., et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int. J. Radiat. Biol 2003, 79:137-143.
18. Von Pfeil A., Hakenjos L., Herskind C., Dittmann K., Weller M., Rodemann H.P. Irradiated homozygous TGF-beta1 knockout fibroblasts show enhanced clonogenic survival as compared with TGF-beta1 wild-type fibroblasts. Int. J. Radiat. Biol 2002, 78:331-339.
19. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010, 2010.
20. Hayden M.S., West A.P., Ghosh S. NF-kappaB and the immune response. Oncogene 2006, 25:6758-6780.
21. Wu Z.H., Shi Y., Tibbetts R.S., Miyamoto S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 2006, 311:1141-1146.
22. Barcellos-Hoff M.H., Dix T.A. Redox-mediated activation of latent transforming growth factor-beta 1. Mol. Endocrinol 1996, 10:1077-1083.
23. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
24. Ehrhart E.J., Segarini P., Tsang M.L., Carroll A.G., Barcellos-Hoff M.H. Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation. FASEB J. 1997, 11:991-1002.
25. Schaue D., Kachikwu E.L., McBride W.H. Cytokines in radiobiological responses: a review. Radiat. Res 2012, 178:505-523.
26. Ding N.-H., Li J.J., Sun L.-Q. Molecular mechanisms and treatment of radiation-induced lung fibrosis. Curr. Drug Targets 2013, 14:1247.
27. Provatopoulou X., Athanasiou E., Gounaris A. Predictive markers of radiation pneumonitis. Anticancer Res 2008, 28:2421-2432.
28. Zhang M., Yin L., Zhang K., Sun W., Yang S., Zhang B., et al. Response patterns of cytokines/chemokines in two murine strains after irradiation. Cytokine 2012, 58:169-177.
29. Desai S., Kumar A., Laskar S., Pandey B. Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. Cytokine 2013, 61:54-62.
30. Liu M., Guo S., Stiles J.K. The emerging role of CXCL10 in cancer (Review). Oncol. Lett 2011, 2:583-589.
31. Rossi D.L., Vicari A.P., Franz-Bacon K., McClanahan T.K., Zlotnik A. Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3alpha and MIP-3beta. J. Immunol 1997, 158:1033-1036.
32. Conti I., Rollins B.J. CCL2 (Monocyte Chemoattractant Protein-1) and Cancer 2004, 149-154. Elsevier, Amsterdam.
33. Malik I.A., Moriconi F., Sheikh N., Naz N., Khan S., Dudas J., et al. Single-dose gamma-irradiation induces up-regulation of chemokine gene expression and recruitment of granulocytes into the portal area but not into other regions of rat hepatic tissue. Am. J. Pathol 2010, 176:1801-1815.
34. Thomson A.W., Lotze M.T. The Cytokine Handbook, Two-Volume Set 2003, Gulf Professional Publishing, Oxford, United Kindom.
35. Guo R.-F., Lentsch A.B., Warner R.L., Huber-Lang M., Sarma J.V., Hlaing T., et al. Regulatory effects of eotaxin on acute lung inflammatory injury. J. Immunol 2001, 166:5208-5218.
36. Lilly C., Nakamura H., Kesselman H., Nagler-Anderson C., Asano K., Garcia-Zepeda E., et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J. Clin. Invest 1997, 99:1767.
37. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
38. Royall J.A., Berkow R.L., Beckman J.S., Cunningham M.K., Matalon S., Freeman B.A. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am. J. Physiol 1989, 257:L399-L410.
39. Murakami M., Nguyen L.T., Hatanaka K., Schachterle W., Chen P.Y., Zhuang Z.W., et al. FGF-dependent regulation of VEGF receptor 2 expression in mice. J. Clin. Invest 2011, 121:2668-2678.
40. Shin S.C., Lee K.M., Kang Y.M., Kim K., Kim C.S., Yang K.H., et al. Alteration of cytokine profiles in mice exposed to chronic low-dose ionizing radiation. Biochem. Biophys. Res. Commun 2010, 397:644-649.
41. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol 2010, 11:7-13.
42. Metcalf D. Hematopoietic cytokines. Blood 2008, 111:485-491.
43. Ihle J.N., Keller J., Oroszlan S., Henderson L.E., Copeland T.D., Fitch F., et al. Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J. Immunol 1983, 131:282-287.
44. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med 2012, 18:1028-1040.
45. Karakasilioti I., Kamileri I., Chatzinikolaou G., Kosteas T., Vergadi E., Robinson A.R., et al. DNA damage triggers a chronic autoinflammatory response, leading to fat depletion in NER progeria. Cell Metab 2013, 18:403-415.
46. Yan B., Peng Y., Li C.Y. Molecular analysis of genetic instability caused by chronic inflammation. Methods Mol. Biol 2009, 512:15-28.
47. Hatzi V.I., Laskaratou D.A., Mavragani I.V., Nikitaki Z., Mangelis A., Panayiotidis M.I., et al. Non-targeted radiation effects in vivo: a critical glance of the future in radiobiology. Cancer Lett 2015, 356:34-42.
48. Siva S., MacManus M.P., Martin R.F., Martin O.A. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett 2015, 356:82-90.
49. Sprung C.N., Ivashkevich A., Forrester H.B., Redon C.E., Georgakilas A., Martin O.A. Oxidative DNA damage caused by inflammation may link to stress-induced non-targeted effects. Cancer Lett 2015, 356:72-81.
50. Emami B., Lyman J., Brown A., Coia L., Goitein M., Munzenrider J.E., et al. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys 1991, 21:109-122.
51. Mancini M.L., Sonis S.T. Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities. Front. Pharmacol 2014, 5:51.
52. Chen Y., Williams J., Ding I., Hernady E., Liu W., Smudzin T., et al. Radiation pneumonitis and early circulatory cytokine markers. Semin. Radiat. Oncol 2002, 12:26-33.
53. Gallet P., Phulpin B., Merlin J.-L., Leroux A., Bravetti P., Mecellem H., et al. Long-term alterations of cytokines and growth factors expression in irradiated tissues and relation with histological severity scoring. PLoS ONE 2011, 6:e29399.
54. Arpin D., Perol D., Blay J.-Y., Falchero L., Claude L., Vuillermoz-Blas S., et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J. Clin. Oncol 2005, 23:8748-8756.
55. Sonnenberg G.F., Nair M.G., Kirn T.J., Zaph C., Fouser L.A., Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J. Exp. Med 2010, 207:1293-1305.
56. Naito Y., Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol. Aspects Med 2005, 26:379-390.
57. Lakos G., Takagawa S., Chen S.J., Ferreira A.M., Han G., Masuda K., et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am. J. Pathol 2004, 165:203-217.
58. Vozenin-Brotons M.C., Milliat F., Sabourin J.C., de Gouville A.C., Francois A., Lasser P., et al. Fibrogenic signals in patients with radiation enteritis are associated with increased connective tissue growth factor expression. Int. J. Radiat. Oncol. Biol. Phys 2003, 56:561-572.
59. Westbury C.B., Yarnold J.R. Radiation fibrosis - current clinical and therapeutic perspectives. Clin. Oncol. (R. Coll. Radiol.) 2012, 24:657-672.
60. Wynn T.A. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med 2011, 208:1339-1350.
61. Schaue D., McBride W.H. Links between innate immunity and normal tissue radiobiology. Radiat. Res 2010, 173:406-417.
62. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest 2005, 115:56-65.
63. Pardo A., Barrios R., Gaxiola M., Segura-Valdez L., Carrillo G., Estrada A., et al. Increase of lung neutrophils in hypersensitivity pneumonitis is associated with lung fibrosis. Am. J. Respir. Crit. Care Med 2000, 161:1698-1704.
64. Chrzanowska K.H., Gregorek H., Dembowska-Baginska B., Kalina M.A., Digweed M. Nijmegen breakage syndrome (NBS). Orphanet J. Rare Dis 2012, 7:13.
65. Aoki F., Kurabayashi M., Hasegawa Y., Kojima I. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. Am. J. Respir. Crit. Care Med 2005, 172:713-720.
66. Patella S., Phillips D.J., Tchongue J., de Kretser D.M., Sievert W. Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol 2006, 290:G137-G144.
67. Forrester H.B., Ivashkevich A., McKay M.J., Leong T., Kretser D.M.D., Sprung C.N. Follistatin is induced by ionizing radiation and potentially predictive of radiosensitivity in radiation-induced fibrosis patient-derived fibroblasts. PLoS ONE 2013.
68. Kis E., Szatmari T., Keszei M., Farkas R., Esik O., Lumniczky K., et al. Microarray analysis of radiation response genes in primary human fibroblasts. Int. J. Radiat. Oncol. Biol. Phys 2006, 66:1506-1514.
69. Sprung C.N., Li J., Hovan D., McKay M.J., Forrester H.B. Alternative transcript initiation and splicing as a response to DNA damage. PLoS ONE 2011, 6:e25758.
70. Duarte C.W., Willey C.D., Zhi D., Cui X., Harris J.J., Vaughan L.K., et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS ONE 2012, 7:e29653.
71. Khodarev N.N., Roach P., Pitroda S.P., Golden D.W., Bhayani M., Shao M.Y., et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS ONE 2009, 4:e5821.
72. Weichselbaum R.R., Ishwaran H., Yoon T., Nuyten D.S., Baker S.W., Khodarev N., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18490-18495.
73. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol 2007, 25:267-296.
74. Gridley D.S., Loredo L.N., Slater J.D., Archambeau J.O., Bedros A.A., Andres M.L., et al. Pilot evaluation of cytokine levels in patients undergoing radiotherapy for brain tumor. Cancer Detect. Prev 1998, 22:20-29.
75. Johnston C.J., Williams J.P., Okunieff P., Finkelstein J.N. Radiation-induced pulmonary fibrosis: examination of chemokine and chemokine receptor families. Radiat. Res 2002, 157:256-265.
76. McBride W.H., Chiang C.-S., Olson J.L., Wang C.-C., Hong J.-H., Pajonk F., et al. A sense of danger from radiation 1. Radiat. Res 2004, 162:1-19.
77. Anscher M.S., Kong F.-M., Andrews K., Clough R., Marks L.B., Bentel G., et al. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys 1998, 41:1029-1035.
78. Ishii Y., Kitamura S. Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis. Eur. Respir. J. 1999, 13:733-738.
79. Vujaskovic H.G. Z, TGF-beta, radiation-induced pulmonary injury and lung cancer. Int. J. Radiat. Biol 2000, 76:511-516.
80. De Jaeger K., Seppenwoolde Y., Kampinga H.H., Boersma L.J., Belderbos J.S., Lebesque J.V. Significance of plasma transforming growth factor-β levels in radiotherapy for non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys 2004, 58:1378-1387.
81. 30 and transforming growth factor β. Int. J. Radiat. Oncol. Biol. Phys 2001, 50:899-908.
82. Takahashi H., Imai Y., Fujishima T., Shiratori M., Murakami S., Chiba H., et al. Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. Eur. Respir. J. 2001, 17:481-487.
83. Novakova-Jiresova A., van Gameren M.M., Coppes R.P., Kampinga H.H., Groen H.J. Transforming growth factor-β plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother. Oncol 2004, 71:183-189.
84. Chen Y., Hyrien O., Williams J., Okunieff P., Smudzin T., Rubin P. Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys 2005, 62:260-266.
85. Hart J.P., Broadwater G., Rabbani Z., Moeller B.J., Clough R., Huang D., et al. Cytokine profiling for prediction of symptomatic radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys 2005, 63:1448-1454.
86. Evans E.S., Kocak Z., Zhou S.-M., Kahn D.A., Huang H., Hollis D.R., et al. Does transforming growth factor-β1 predict for radiation-induced pneumonitis in patients treated for lung cancer?. Cytokine 2006, 35:186-192.
87. Rübe C.E., Palm J., Erren M., Fleckenstein J., König J., Remberger K., et al. Cytokine plasma levels: reliable predictors for radiation pneumonitis?. PLoS ONE 2008, 3:e2898.
88. Zhao L., Wang L., Ji W., Wang X., Zhu X., Hayman J.A., et al. Elevation of plasma TGF-β1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. Int. J. Radiat. Oncol. Biol. Phys 2009, 74:1385-1390.
89. Siva S., MacManus M., Kron T., Best N., Smith J., Lobachevsky P., et al. A pattern of early radiation-induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell lung cancer. PLoS ONE 2014, 9:e109560.
90. Anscher M.S., Murase T., Prescott D.M., Marks L.B., Reisenbichler H., Bentel G.C., et al. Changes in plasma TGF [beta] levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys 1994, 30:671-676.
91. Chen Y., Rubin P., Williams J., Hernady E., Smudzin T., Okunieff P. Circulating IL-6 as a predictor of radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys 2001, 49:641-648.
92. Anscher M.S., Kong F.-M., Marks L.B., Bentel G.C., Jirtle R.L. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int. J. Radiat. Oncol. Biol. Phys 1997, 37:253-258.
93. Crohns M., Saarelainen S., Laine S., Poussa T., Alho H., Kellokumpu-Lehtinen P. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - association of interleukin-8 and VEGF with survival. Cytokine 2010, 50:30-36.